Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. (Q51768350)

From Wikidata

Jump to navigation Jump to search

scientific article published on 13 March 2009

Language	Label	Description	Also known as
English	Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.	scientific article published on 13 March 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/19287371

Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/19287371

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

J Nemunaitis

1

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/19287371

M Nemunaitis

2

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/19287371

N Senzer

3

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/19287371

P Snitz

4

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/19287371

C Bedell

5

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/19287371

P Kumar

6

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/19287371

B Pappen

7

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/19287371

P B Maples

8

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/19287371

D Shawler

9

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/19287371

H Fakhrai

10

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/19287371

publication date

13 March 2009

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/19287371

Cancer Gene Therapy

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/19287371

16

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/19287371

8

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/19287371

620-624

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/19287371

The TGF-beta family of growth and differentiation factors.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Transforming growth factor-beta in disease: the dark side of tissue repair

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Transforming growth factor-beta inhibits interferon-gamma secretion by lymphokine-activated killer cells stimulated with tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

The development of immunotherapies for non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Vaccines in cancer: GVAX, a GM-CSF gene vaccine

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Deactivation of macrophages by transforming growth factor-β

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

21 January 2018

Transforming growth factor-beta: biological function and chemical structure

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of combined immunotherapy, chemotherapy, and radiotherapy in the postoperative treatment of advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.15

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CGT.2009.15

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/19287371

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/19287371

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51768350&oldid=2211190152"